stockrow
Monday 9 November 2026
Export MDWD’s income statement to Excel — free account
MediWound Ltd.
MDWDMediWound Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.0 million, down 16.1% from fiscal 2024.
- Revenue
- −45.8%
- EPS
- +53.7%
- Free cash flow
- −49.9%
- Total debt
- +51.8%
Quarter to June 2026, against a year earlier
14.25
0.92
+6.90%
Follow MDWD
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 2 | 2 | 3 | 32 | 22 | 24 | 26 | 19 | 20 | 17 | 12 | +30.4% | 24 | 32 | 47 | +40.6% | |
| Gross margin, % | (38.51) | 36.78 | 38.61 | 62.73 | 34.67 | 36.91 | 49.69 | 19.15 | 13.03 | 19.19 | 15.46 | +57.7 pt | ||||||
| EBT | (19) | (15) | (6) | 2 | (9) | (14) | (20) | (7) | (30) | (24) | (20) | +2.6% | ||||||
| EBT margin, % | (1,212.13) | (582.25) | (166.57) | 6.50 | (42.62) | (56.91) | (73.68) | (34.95) | (149.16) | (139.81) | (168.90) | +1,072.3 pt | ||||||
| Net income | (19) | (22) | (1) | 5 | (9) | (14) | (20) | (7) | (30) | (24) | (20) | +2.6% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.50 | 0.75 | 0.88 | 8.18 | 5.60 | 6.11 | 5.31 | 2.07 | 2.03 | 1.49 | 0.92 | +12.9% | |||||
| Earnings | (6.02) | (6.65) | (0.28) | 1.26 | (2.38) | (3.50) | (3.93) | (0.75) | (3.03) | (2.10) | (1.60) | (11.0%) | ||||||
| Cash flow | (5.26) | (4.93) | (3.14) | 2.13 | (1.77) | (2.29) | (2.38) | (1.16) | (1.37) | (1.42) | (1.72) | (13.6%) | ||||||
| Capex | (0.22) | (0.32) | (0.14) | (0.20) | (0.24) | (0.13) | (0.11) | (0.72) | (0.63) | (0.48) | (0.50) | +8.9% | ||||||
| Free cash flow | (5.49) | (5.26) | (3.27) | 1.93 | (2.01) | (2.42) | (2.49) | (1.88) | (2.00) | (1.90) | (2.21) | (11.1%) | ||||||
| Book value | 2.49 | 2.88 | 2.32 | 3.91 | 1.87 | (1.18) | 2.19 | 3.51 | 3.13 | 3.84 | 2.77 | +4.9% | ||||||
| Shares, m | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 9 | 10 | 11 | 12 | +15.4% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 2.46 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.2 | |||||
| P/S | 10.53 | 6.08 | 4.63 | 0.38 | 0.66 | 0.39 | 2.50 | 5.43 | 8.77 | 12.38 | 15.48 | 5.2 | ||||||
| P/B | 2.11 | 1.58 | 1.75 | 0.79 | 1.98 | 0.00 | 6.07 | 3.21 | 5.69 | 4.81 | 5.15 | 2.8 | ||||||
| EV/Sales | (8.66) | (8.31) | (2.28) | (0.53) | (0.30) | (0.05) | 1.24 | 3.31 | 6.66 | 9.30 | 12.58 | 0.0 | ||||||
| EV/FCF | 0.78 | 1.18 | 0.61 | (2.26) | 0.84 | 0.13 | (2.64) | (3.64) | (6.76) | (7.28) | (5.22) | (1.9) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (16) | (16) | (12) | 8 | (7) | (9) | (12) | (10) | (14) | (16) | (22) | (0.2%) | |||||
| Capex | (1) | (1) | (1) | (1) | (1) | 0 | (1) | (6) | (6) | (6) | (6) | +25.7% | ||||||
| Free cash flow | (17) | (18) | (13) | 7 | (8) | (9) | (12) | (17) | (20) | (22) | (29) | +2.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 28 | 36 | 28 | 25 | 18 | 4 | 34 | 32 | 26 | 34 | 24 | +2.2% | |||||
| Net debt | (30) | (36) | (24) | (29) | (22) | (11) | (34) | (42) | (43) | (53) | (35) | +6.5% | ||||||
| Shareholders’ equity | 8 | 10 | 9 | 15 | 7 | (5) | 11 | 32 | 31 | 44 | 36 | +21.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (42.78) | (55.44) | (2.66) | 13.06 | (25.67) | (53.34) | (56.19) | (11.53) | (43.19) | (29.90) | (29.06) | +12.9 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (6,551.77) | 0.0 pt | ||||||
| ROE | (120.90) | (254.73) | (11.37) | 41.05 | (81.96) | (1,007.51) | (619.05) | (31.60) | (96.33) | (63.86) | (75.42) | +57.0 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 72 | 76 | 61 | 74 | 75 | 77 | 83 | 88 | 111 | 121 | — | +5.9% | |||||
| Revenue/emp, $m | 0.02 | 0.03 | 0.06 | 0.43 | 0.29 | 0.31 | 0.32 | 0.21 | 0.18 | 0.14 | — | +23.1% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
MediWound Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics, Inc. | $191.5M | — (loss-making) | — (loss-making) | −43.93% (below 0%: shrinking) | n/m | −7.05% (below 0%: shrinking) | 100.00% | (4,606.52%) | Compare |
| CGEN Compugen Ltd. | $185.7M | 5.2× | — (loss-making) | +107.00% (above 0%: growing) | n/m | −155.42% (below 0%: shrinking) | (3.54%) | (339.62%) | Compare |
| MDWD MediWound Ltd. | $184.0M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | $182.5M | — (loss-making) | — (loss-making) | +190.24% (above 0%: growing) | n/m | +43.48% (above 0%: growing) | 100.00% | (39.57%) | Compare |
| ACOG Alpha Cognition Inc. | $180.5M | — (loss-making) | — (loss-making) | +267.56% (above 0%: growing) | n/m | −109.25% (below 0%: shrinking) | 94.80% | (127.29%) | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $178.4M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| UPB Upstream Bio, Inc. | $176.9M | — (loss-making) | — (loss-making) | −17.50% (below 0%: shrinking) | n/m | +9.33% (above 0%: growing) | 100.00% | (5,480.98%) | Compare |
| IVVD Invivyd, Inc. | $166.0M | — (loss-making) | — (loss-making) | +21.20% (above 0%: growing) | n/m | −226.89% (below 0%: shrinking) | 91.09% | (320.76%) | Compare |
| BBOT BridgeBio Oncology Therapeutics, Inc | $163.6M | — (loss-making) | — | — | n/m | −88.78% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $179.5M | — | — | +33.48% | — | −47.91% | 94.80% | (224.02%) |